Ozempic nausea, Zepbound nausea and the other GLP-1 labels
The short answer
Ozempic nausea is the most frequently reported reaction in that label's table: 15.8% to 20.3% of adults, against 6.1% on placebo. All eight GLP-1 labels list nausea. In adult trials it was reported by 44% of patients on Wegovy 2.4 mg (16% on placebo) and 25% to 29% on Zepbound (8% on placebo). Several labels tie it to dose increases. If it keeps you from eating or drinking normally, tell your prescriber.
Key takeaways
- All eight GLP-1 labels list nausea, and several tie it to the weeks when the dose is being raised.
- No label says how long an episode of nausea lasts.
- Tell your prescriber if nausea keeps you from eating or drinking normally, or doesn't ease after a dose increase.
- Nausea with vomiting or diarrhea can leave you dehydrated, and the labels link dehydration to kidney injury.
- Severe or persistent abdominal pain needs prompt medical attention.
How often it was reported in the label's trials
| Reaction | Placebon=958 | 5 mgn=630 | 10 mgn=948 | 15 mgn=941 |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Reaction | Placebon=235 | 5 mgn=237 | 10 mgn=240 | 15 mgn=241 |
|---|---|---|---|---|
| Nausea | 4% | 12% | 15% | 18% |
| Reaction | Placebon=1261 | Wegovy injection 2.4 mg once weeklyn=2116 |
|---|---|---|
| Nausea | 16% | 44% |
| Reaction | Placebon=303 | Wegovy injection 2.4 mg once weeklyn=304 | Wegovy injection 7.2 mg once weeklyn=1311 |
|---|---|---|---|
| Nausea | 13% | 35% | 39% |
| Reaction | Placebon=67 | Wegovy injection 2.4 mg once weeklyn=133 |
|---|---|---|
| Nausea | 18% | 42% |
| Reaction | Placebon=262 | Ozempic 0.5 mgn=260 | Ozempic 1 mgn=261 |
|---|---|---|---|
| Nausea | 6.1% | 15.8% | 20.3% |
| Reaction | Placebon=1576 | 5.5 mgn=1051 | 9 mgn=1055 | 17.2 mgn=1049 |
|---|---|---|---|---|
| Nausea | 10% | 26% | 34% | 35% |
| Reaction | Placebon=362 | Semaglutide tablets 7 mgn=356 | Semaglutide tablets 14 mgn=356 |
|---|---|---|---|
| Nausea | 6% | 11% | 20% |
| Reaction | Placebon=1941 | Saxendan=3384 |
|---|---|---|
| Nausea | 13.8% | 39.3% |
| Reaction | Placebon=126 | Saxendan=125 |
|---|---|---|
| Nausea | 14.3% | 42.4% |
| Reaction | Placebon=568 | 0.75 mgn=836 | 1.5 mgn=834 |
|---|---|---|---|
| Nausea | 5.3% | 12.4% | 21.1% |
| Reaction | 1.5 mgn=612 | 3 mgn=616 | 4.5 mgn=614 |
|---|---|---|---|
| Nausea | 13.4% | 15.6% | 16.4% |
Each medicine's figures come from its own trials, which differ in dose, length and who took part. They are not a head-to-head comparison.
Feeling sick to your stomach on a GLP-1? Tell your prescriber if nausea keeps you from eating or drinking normally, if it comes with vomiting or diarrhea that could leave you dehydrated, or if it doesn’t ease after a dose increase. Severe or persistent abdominal pain needs prompt medical attention.
Nausea is the one reaction all eight labels put in their tables, and in most of them it’s the top row. The tables below show every label’s figures, and this page explains how to read them.
How often do the labels report nausea?
Each figure is the share of trial patients who reported nausea at least once. Next to it is the placebo group from the same trials. A placebo group gets an inactive treatment instead of the medicine.
Weight management trials in adults
- Wegovy 2.4 mg injection (three trials, up to 68 weeks): 44%, with 16% on placebo. In the separate trials of the 7.2 mg dose in adults with obesity, 39% on 7.2 mg, 35% on 2.4 mg and 13% on placebo.
- Zepbound (two pooled trials, up to 72 weeks): 25% at 5 mg, 29% at 10 mg and 28% at 15 mg, with 8% on placebo.
- Foundayo (two pooled trials, up to 72 weeks): 26% at 5.5 mg, 34% at 9 mg and 35% at 17.2 mg, with 10% on placebo.
- Saxenda (five trials): 39.3%, with 13.8% on placebo.
Type 2 diabetes trials in adults
- Ozempic injection (two trials): 15.8% at 0.5 mg and 20.3% at 1 mg, with 6.1% on placebo.
- Mounjaro (two pooled trials): 12% at 5 mg, 15% at 10 mg and 18% at 15 mg, with 4% on placebo.
- Rybelsus (two trials; the label also covers Ozempic tablets): 11% at 7 mg and 20% at 14 mg, with 6% on placebo.
- Trulicity (pooled trials): 12.4% at 0.75 mg and 21.1% at 1.5 mg, with 5.3% on placebo. In a later trial with no placebo arm: 13.4% at 1.5 mg, 15.6% at 3 mg and 16.4% at 4.5 mg.
Adolescents aged 12 and older with obesity
- Wegovy 2.4 mg: 42%, with 18% on placebo.
- Saxenda: 42.4%, with 14.3% on placebo.
These are separate trials in different groups of people, so you can’t line the numbers up to say which medicine causes less nausea. Look at the placebo rows too. Between 4% and 18% of people who got no active drug also reported nausea.
When does nausea happen?
Mostly while the dose is being raised, which the labels call dose escalation. Here’s what the labels that address timing say:
- Zepbound: the majority of nausea, vomiting and diarrhea events “occurred during dose escalation and decreased over time.”
- Foundayo: the incidence “was higher during the FOUNDAYO dosage escalation period and decreased over time.”
- Ozempic and Rybelsus: the majority of reports occurred during dose escalation.
- Wegovy: gastrointestinal reactions “were most frequently reported during dosage escalation.”
- Saxenda: “The percentage of patients reporting nausea declined as treatment continued.”
No label says how long an episode lasts.
Every one of these medicines starts at a low dose and steps up for this reason. The titration schedule tool shows when each step falls for your medicine. Whether to stay longer on a dose because of nausea is your prescriber’s decision. The label doesn’t leave that to you.
Which warnings relate to nausea?
Two, and they’re the reason to report nausea, not put up with it in silence.
Dehydration and kidney injury. Every label carries a warning about acute kidney injury due to volume depletion, meaning losing too much fluid. Zepbound’s describes postmarketing reports (reports made after approval) of acute kidney injury, “in some cases requiring hemodialysis,” a treatment in which a machine filters the blood. It says the majority occurred in patients whose nausea, vomiting or diarrhea led to dehydration. The Wegovy and Rybelsus labels tell prescribers to monitor kidney function in patients who report reactions that could lead to volume depletion, especially while the dose is being started and raised.
Pancreatitis. The Wegovy, Ozempic and Saxenda labels describe the signs of acute pancreatitis, an inflammation of the pancreas, as persistent or severe abdominal pain, sometimes radiating to the back, “which may or may not be accompanied by nausea or vomiting.” Nausea alone is common. Nausea alongside that kind of pain is different. See abdominal pain.
The labels also warn that stomach and bowel reactions are sometimes severe, and they say the medicines are not recommended in people with severe gastroparesis (a stomach that empties very slowly).
When to contact your prescriber
The label text is written for clinicians, and it asks them to act on what patients report. So speak up. Tell your prescriber if nausea is keeping you from eating or drinking normally, if it comes with vomiting or diarrhea that could leave you dehydrated, or if it doesn’t ease after a dose increase. Severe or persistent abdominal pain needs prompt medical attention.
Your pharmacist can tell you what’s appropriate for nausea with your other medicines. For the wider picture, see the side effects guide.
Frequently asked questions
Does Ozempic cause nausea?
Yes, it's the most frequently reported reaction in the Ozempic injection label's table. In two placebo-controlled trials in adults with type 2 diabetes, 15.8% of patients on 0.5 mg and 20.3% on 1 mg reported it, compared with 6.1% on placebo. The label says most reports of nausea, vomiting and diarrhea came during dose escalation, the weeks when the dose is being raised.
How long does nausea last on Wegovy or Zepbound?
Neither label gives a number of days or weeks. Wegovy's says stomach and bowel reactions were most frequently reported during dosage escalation, while the dose was being raised. Zepbound's says most nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time. That describes the whole trial group, not what you personally should expect. If your nausea won't go away, raise it with your prescriber.
Is nausea worse at higher doses?
It depends on the label. Mounjaro's table shows 12% at 5 mg, 15% at 10 mg and 18% at 15 mg. Zepbound's shows 25%, 29% and 28% for the same three doses, so the top dose wasn't the highest. Rybelsus shows 11% at 7 mg and 20% at 14 mg. The labels tie nausea more firmly to the weeks of raising the dose than to any one dose.
Do people stop their GLP-1 because of nausea?
Some do. In the adult Wegovy 2.4 mg trials, nausea led 1.8% of patients to stop for good, against 0.2% on placebo, and it was the most common reaction behind stopping. In the adult Saxenda trials the figures were 2.9% and 0.2%. If nausea has you thinking about stopping, talk to your prescriber first.
Does Zepbound cause nausea?
Yes, nausea is in the Zepbound label's table. In two pooled weight reduction trials of up to 72 weeks, 25% of patients on 5 mg, 29% on 10 mg and 28% on 15 mg reported it, compared with 8% on placebo. The label says most nausea, vomiting and diarrhea events occurred during dose escalation (while the dose was being raised) and decreased over time.
Sources (8)
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
Related pages
- GLP-1 side effects: what the FDA labels report
- Vomiting on Wegovy, Zepbound, Ozempic and other GLP-1 medicines
- Ozempic diarrhea: what the GLP-1 labels report
- Dyspepsia and indigestion on Zepbound, Wegovy, Mounjaro and other GLP-1 medicines
- Titration schedule builder
- Abdominal pain on Wegovy, Zepbound, Ozempic and other GLP-1 medicines
